Association of Allostatic Load With Overall Mortality Among Patients With Metastatic Non–Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.21626
Abstract: Key Points Question Is there an association among allostatic load (AL), social determinants of health (SDHs), and overall mortality in patients with metastatic non–small cell lung cancer (NSCLC)? Findings In this cross-sectional study of 143… read more here.
Keywords: non small; metastatic non; patients metastatic; overall mortality ... See more keywords
Exceptional pemetrexed sensitivity can predict therapeutic benefit from subsequent chemotherapy in metastatic non-squamous non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-019-02941-z
Abstract: PurposeBased on an exceptionally durable response to pemetrexed observed in some patients with metastatic NSCLC, the predictive value of pemetrexed sensitivity to outcomes of subsequent systemic treatment was investigated.MethodsWe retrospectively reviewed the patients with metastatic… read more here.
Keywords: chemotherapy; metastatic non; non squamous; treatment ... See more keywords
Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-021-03527-4
Abstract: Although immune-checkpoint inhibitors have become a new therapeutic option for recurrent/metastatic non-small cell lung cancers (R/M-NSCLC), its clinical benefit in the real-world is still unclear. We investigated 1181 Korean patients with programmed death-1 ligand 1… read more here.
Keywords: recurrent metastatic; real world; metastatic non; group ... See more keywords
Immune Checkpoint Inhibition in Non-metastatic Non-small Cell Lung Cancer: Chance for Cure?
Sign Up to like & getrecommendations! Published in 2019 at "Drugs"
DOI: 10.1007/s40265-019-01222-w
Abstract: Immune checkpoint inhibition of programmed-death receptor 1 (PD-1) or its ligand (PD-L1) has become a standard in the treatment of metastatic non-small cell lung cancer, either as monotherapy or in combination. Recently, it could be… read more here.
Keywords: immune checkpoint; metastatic non; cell lung; checkpoint inhibition ... See more keywords
Q-TWiST Analysis to Assess Benefit–Risk of Pembrolizumab in Patients with PD-L1–Positive Advanced or Metastatic Non-small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2018 at "Pharmacoeconomics"
DOI: 10.1007/s40273-018-0752-0
Abstract: ObjectivesPembrolizumab monotherapy showed significantly longer overall survival and fewer treatment-related adverse events compared to chemotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with programmed death ligand-1 (PD-L1)–positive tumors in the first-line… read more here.
Keywords: advanced metastatic; non small; metastatic non; analysis ... See more keywords
Outcomes of Patients With Metastatic Non–Clear‐Cell Renal Cell Carcinoma Treated With Pazopanib
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Genitourinary Cancer"
DOI: 10.1016/j.clgc.2016.07.016
Abstract: Micro‐Abstract Outcomes data in patients with metastatic non–clear‐cell renal cell carcinoma (RCC) treated with pazopanib are limited. We identified 29 patients with non–clear‐cell metastatic RCC who received pazopanib (9 in the front‐line setting, and 20… read more here.
Keywords: non clear; metastatic non; front line; cell ... See more keywords
Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients.
Sign Up to like & getrecommendations! Published in 2019 at "Clinical nutrition"
DOI: 10.1016/j.clnu.2019.08.003
Abstract: BACKGROUND & AIMS Metastatic non-small cell lung cancer (NSCLC) is the first cause of cancer death worldwide. Increased resting energy expenditure (REE) is frequent among cancer patients and may contribute to cancer cachexia. The aim… read more here.
Keywords: metastatic non; cell lung; independent prognostic; non small ... See more keywords
Metastatic non-Hematopoietic Neoplasms to the Breast: A Study of 238 Cases.
Sign Up to like & getrecommendations! Published in 2022 at "Human pathology"
DOI: 10.1016/j.humpath.2022.04.009
Abstract: AIMS The aim of this study was to review the clinicopathologic characteristics of metastatic non-hematopoietic malignancies to the breast, in order to identify salient features for practicing pathologist that are useful in distinguishing metastatic lesions… read more here.
Keywords: metastatic non; 238 cases; non hematopoietic; study ... See more keywords
Changing costs of metastatic non small cell lung cancer in the Netherlands.
Sign Up to like & getrecommendations! Published in 2017 at "Lung cancer"
DOI: 10.1016/j.lungcan.2017.10.005
Abstract: OBJECTIVES The primary objective of this study was to identify the total intramural cost of illness of metastatic non-small cell lung cancer (NSCLC) in the Netherlands between 2006-2012. Secondary objective was to identify whether changes… read more here.
Keywords: non small; metastatic non; metastatic nsclc; lung cancer ... See more keywords
Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations
Sign Up to like & getrecommendations! Published in 2019 at "Expert Review of Respiratory Medicine"
DOI: 10.1080/17476348.2020.1701439
Abstract: ABSTRACT Introduction: Cancer immunotherapy has revolutionized the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC). However, specific patient groups (e.g. patients with activating epidermal growth factor receptor [EGFR] mutations) do not… read more here.
Keywords: metastatic non; egfr mutations; treatment; treatment patients ... See more keywords
A nomogram for predicting overall survival rate in patients with brain metastatic non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000030824
Abstract: The purpose was to develop a nomogram for the prediction of the 1- and 2-year overall survival (OS) rates in patients with brain metastatic non-small cell lung cancer (BMNSCLC). Patients were collected from the Surveillance… read more here.
Keywords: brain metastatic; non small; metastatic non; patients brain ... See more keywords